Cite
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
MLA
Karim A. Benhadji, et al. “A Phase I, Open-Label Study Evaluating the Safety and Pharmacokinetics of Trifluridine/Tipiracil in Patients with Advanced Solid Tumors and Varying Degrees of Renal Impairment.” Cancer Chemotherapy and Pharmacology, vol. 88, June 2021, pp. 485–97. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4248748f5db1a31dcf2ea0b45dc04d2c&authtype=sso&custid=ns315887.
APA
Karim A. Benhadji, Lee S. Rosen, Muhammad Wasif Saif, Smitha S. Krishnamurthi, Carlos Becerra, Thomas J. George, Weijing Sun, Vladimir Sramek, Marwan Fakih, Bojan Zaric, Ikuo Yamamiya, Jiri Skopek, Yaohua He, Kensuke Hamada, Michelle A. Rudek, Lazar Popovic, & Dale R. Shepard. (2021). A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemotherapy and Pharmacology, 88, 485–497.
Chicago
Karim A. Benhadji, Lee S. Rosen, Muhammad Wasif Saif, Smitha S. Krishnamurthi, Carlos Becerra, Thomas J. George, Weijing Sun, et al. 2021. “A Phase I, Open-Label Study Evaluating the Safety and Pharmacokinetics of Trifluridine/Tipiracil in Patients with Advanced Solid Tumors and Varying Degrees of Renal Impairment.” Cancer Chemotherapy and Pharmacology 88 (June): 485–97. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4248748f5db1a31dcf2ea0b45dc04d2c&authtype=sso&custid=ns315887.